Fidelity MSCI COnsumer Staples Index ETF (ARCA: FSTA)

最新ニュース Fidelity MSCI COnsumer Staples Index ETF (ARCA:FSTA)

Fidelity MSCI COnsumer Staples Index ETF

Consumer Defensive

Consumer Cyclical

Healthcare

Industrials

Basic Materials

Other

The fund invests at least 80% of assets in securities included in the funds underlying index. The funds underlying index is the MSCI USA IMI Consumer Staples 25/50 Index, which represents the performance of the consumer staples sector in the U.S. equity market. It may or may not hold all of the securities in MSCI USA IMI Consumer Staples 25/50 Index. The fund is non-diversified.

Procter & Gamble Co

Costco Wholesale Corp

Walmart, Inc.

Pepsico Inc

Philip Morris International Inc

Altria Group Inc

Colgate-Palmolive Co

Target Corp 

Mondelez International Inc Class A

INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) reported quarterly losses of $(9.04) per share. This is a 6.32 percent increase over losses of $(9.65) per share from the same period last year. The company reported $1.69 million in sales this quarter. This is a 22.02 percent increase over sales of $1.38 million the same period last year.

Earnings

News

INVO Fertility Q4 EPS $(9.04) Up From $(9.65) YoY, Sales $1.69M Up From $1.38M YoY

Seaport Global analyst Jay Goldberg initiates coverage on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Sell rating and announces Price Target of $130.

Price Target

Initiation

Analyst Ratings

Seaport Global Initiates Coverage On Texas Instruments with Sell Rating, Announces Price Target of $130

New integration empowers SOC teams to detect and contain unauthorized AI usage with real-time, unified visibility and automated response across the enterprise
RSAC 2025 – <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2F&amp;esheet=54246221&amp;newsitemid=20250430082038&amp;lan=en-US&amp;anchor=CrowdStrike&amp;index=1&amp;md5=84912a545d038b0f2a828e1a5d9cabb6">CrowdStrike</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.extrahop.com%2F&amp;esheet=54246221&amp;newsitemid=20250430082038&amp;lan=en-US&amp;anchor=ExtraHop&amp;index=2&amp;md5=a7d47e8909a33509774a7b80654c6afe">ExtraHop</a> today announced an expanded partnership to help enterprises detect and contain shadow AI risks. By ingesting market-leading network intelligence from ExtraHop into <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2Fnext-gen-siem%2F&amp;esheet=54246221&amp;newsitemid=20250430082038&amp;lan=en-US&amp;anchor=CrowdStrike+Falcon%26%23174%3B+Next-Gen+SIEM&amp;index=3&amp;md5=6cf568f9add27b953b7023c32a073545">CrowdStrike Falcon&#xAE; Next-Gen SIEM</a>, the new integration gives SOC teams real-time visibility into unauthorized AI service usage and the ability to automate response actions – protecting sensitive data without slowing innovation.
Shadow AI is rapidly becoming a critical risk for enterprises as employees use and adopt AI tools outside the visibility of IT and security teams. These tools frequently bypass established security controls, creating blind spots that adversaries can exploit to access sensitive data or introduce misconfigurations that lead to breaches.
To close this gap, CrowdStrike and ExtraHop are giving SOC teams unified visibility and control over AI service usage across endpoints, networks, cloud environments, and on-premises infrastructure. By integrating deep network telemetry from ExtraHop with first- and third-party data from Falcon Next-Gen SIEM and automated remediation from <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2Fnext-gen-siem%2Ffalcon-fusion%2F&amp;esheet=54246221&amp;newsitemid=20250430082038&amp;lan=en-US&amp;anchor=Falcon+Fusion+SOAR&amp;index=4&amp;md5=81d54ae05f4fd6ce13dba42810cbb75c">Falcon Fusion SOAR</a>, security teams can identify unauthorized AI models and agents, visualize usage patterns, and automate containment actions to reduce the risk of sensitive data exposure.
"Shadow AI has quickly emerged as a major security blind spot, often going undetected by legacy tools and exposing sensitive data," said Daniel Bernard, chief business officer, CrowdStrike. "Together with ExtraHop, we're delivering AI-native security and real-time network intelligence that empowers security teams to detect, stop and control unauthorized AI. This integration helps organizations embrace AI innovation without losing visibility, control or protection of sensitive data."
"From the moment commercial AI services began to gain traction, ExtraHop recognized the vital role of network telemetry in providing crucial visibility into their burgeoning use across the enterprise," said Kanaiya Vasani, chief product officer, ExtraHop. "Our deepening partnership with CrowdStrike allows us to build on this foresight, leveraging that visibility to deliver unparalleled insight into the broad spectrum of AI services in use today. Together, we offer organizations a streamlined solution for identifying and mitigating potential security risks from increasing use of AI tools across their environments."
 &nbsp;

Contracts

CRWD

Crowdstrike And Extrahop Expands Partnership To Help Enterprises Detect And Contain Shadow AI Risks By Ingesting ExtraHop Into CrowdStrike Falcon Next-Gen SIEM

Seaport Global analyst Jay Goldberg initiates coverage on Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy rating and announces Price Target of $110.

Seaport Global Initiates Coverage On Advanced Micro Devices with Buy Rating, Announces Price Target of $110

Raymond James analyst Ric Prentiss maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Strong Buy and raises the price target from $231 to $251.

Raymond James Maintains Strong Buy on American Tower, Raises Price Target to $251

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares are moving lower Wednesday in sympathy with Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), which reported preliminary results late Tuesday. Here&#8217;s what <a href="https://www.benzinga.com/news/earnings/25/04/45086254/super-micro-computer-stock-is-tanking-after-hours-whats-fueling-the-sell-off">you need to know</a>.
What Happened: After the market close on Tuesday, Super Micro preannounced expectations for the third quarter due to delayed customer platform decisions that moved sales into the fourth quarter.
The company reported soft preliminary results that sent shares tumbling, including expectations for third-quarter revenue of $4.5 billion to $4.6 billion, down from prior guidance of $5 billion to $6 billion. Super Micro also said it expects to report third-quarter adjusted earnings in the range of 29 cents to 31 cents per share, down from prior guidance of 46 cents to 62 cents per share.
Super Micro also expects gross margin for the third quarter to be 220 basis points lower than the second quarter, primarily due to "higher inventory reserves resulting from older generation products and expedited costs to enable time-to-market for new products."
Check This Out: <a href="https://www.benzinga.com/25/04/45092827/nvidia-to-face-significant-market-loss-in-china-amid-huaweis-ai-chip-development-says-analyst-its-pretty-much-game-over-for-nvidia-in-china">&#8216;It&#8217;s Pretty Much Game Over For Nvidia In China,&#8217; Says Analyst: Here&#8217;s Why</a>
Why It Matters For DELL: Dell is one of Super Micro&#8217;s main competitors, specifically in the <a href="http://benzinga.com/topic/ai">AI</a> space. Both companies offer high-performance server solutions used in enterprise, cloud and AI workloads. 
Dell and Super Micro are key NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) partners, delivering GPU systems for generative AI and machine learning. Both companies take Nvidia's chips, package them into servers and then sell them to AI hyperscalers.
Super Micro shares were last down approximately 19%, dragging Dell and Nvidia down with it. Nvidia shares fell about 2% when Super Micro reported preliminary results. Dell shares fell more than 4% on the news and have continued to move lower Wednesday morning.
Dell is due to report financial results <a href="https://www.benzinga.com/calendars/earnings">for the first quarter</a> sometime next month. Analysts currently expect the company to report earnings of $1.67 per share and revenue of $23.11 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. In the company&#8217;s prior two quarters, Dell beat earnings estimates, but fell short on revenue. 
DELL Price Action: <a href="http://benzinga.com/quote/dell">Dell shares</a> were down 6.27% at $87.90 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Gabriel Pahontu/Shutterstock.

Guidance

Movers

DELL

NVDA

SMCI

Dell Technologies Stock Falls Alongside Super Micro: What's Going On?

Heartland Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLD#NASDAQ">HTLD</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.08) by 125 percent. This is a 5.26 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $219.42 million which missed the analyst consensus estimate of $241.37 million by 9.09 percent. This is a 18.83 percent decrease over sales of $270.32 million the same period last year.

Earnings Misses

HTLD

Heartland Express Q1 EPS $(0.18) Misses $(0.08) Estimate, Sales $219.42M Miss $241.37M Estimate

Stock Split

HSDT

Helius Medical Technologies Announces 1-for-15 Reverse Stock Split, Effective 5:00 p.m. ET May 1

MCRP

Micropolis Holding Signs Non-Legally Binding MoU With SEE Holding To Support Launch And Long-Term Development Of The Sustainable City 2.0

Seaport Global analyst Jay Goldberg initiates coverage on Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Sell rating and announces Price Target of $18.

INTC

Seaport Global Initiates Coverage On Intel with Sell Rating, Announces Price Target of $18

Integrated solution enables Flywire to unlock new payment flows from India to academic destinations worldwide
Flywire further expands footprint in India, capitalizes on the billions of dollars of payment volume from education loans
&nbsp;<a href="https://www.globenewswire.com/Tracker?data=9Pd_EqTdmjSTaEHfDZSfMtsln0U0GCWAIpcMXkv3b8lJpv4PJN-7UUEfEymhYePyquu_DQ4FnYFqO33ELkZt5NnHLrpamqq0gpew7ABjiDM=">Flywire Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) (Flywire), a global payments and enablement and software company, today announced its strategic partnership with<a href="https://www.globenewswire.com/Tracker?data=QJYz4TIXv3PAcQItUyHBnbDbjWZPvBr5iTsFxWXbiVy3wocHZE5LaSPzVccZc6W-XOfZamzSfTZwEhStW5Vjjn0G2dtgF-_wrpL0KKwb3_k="> Avanse Financial Services</a>, India's second-largest education-focused non-banking financial company (NBFC). The collaboration simplifies the process of disbursing education loan payments for Indian students pursuing education opportunities abroad. The collaboration helps Flywire capitalize on tuition loan disbursements initiated by Avanse in Indian Rupees (INR) and builds on Flywire's existing banking and loan integrations in India. The solution is available immediately and supports payment flows from India to academic destinations worldwide.
Through this integration, Flywire streamlines the entire payments experience for students who opt to get educational loans from Avanse. After loan approval, students process payments via Flywire entirely in Indian rupees, with the ability to monitor transactions until funds reach their university. Flywire ensures transparency over all loan disbursements, facilitates efficient refunds, and automates the complex Tax Collected at Source (TCS) calculations—ultimately saving both students and providers valuable time and resources while ensuring adherence to relevant tax guidelines.
"We're excited to collaborate with Avanse to enhance the process of student loan disbursements from India," commented Mina Fakhouri, SVP, APAC &amp; Global Agents at Flywire. "The combination of Avanse's presence in India and Flywire's innovative payment technology addresses a crucial market gap for both students and lending institutions. India remains an important market for Flywire, and we're excited to work together to deliver value to our partners, payers, educational institutions and beyond."
Additional benefits of the integration between Flywire and Avanse are expected to include:
<ul>
<li>Competitive foreign exchange conversion rates for students</li>
<li>Providing transparent payment tracking for students, schools and financial institutions</li>
<li>Enhancing compliance with international banking regulations</li>
<li>Managing TCS calculations for payments</li>
<li>Simplifying the documentation requirements for both students and institutions &nbsp;</li>
</ul>

FLYW

Flywire And Avanse Financial Services Enters Strategic Partnership To Digitize Student Loan Disbursements From India

NHTC

Natural Health Trends Q1 EPS $0.01 Down From $0.02 YoY, Sales $10.70M Down From $10.95M YoY

EHLD

EuroHoldings Ltd. Initiates Review Of Strategic Alternatives

Seaport Global analyst Jay Goldberg initiates coverage on Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Buy rating and announces Price Target of $230.

AVGO

Seaport Global Initiates Coverage On Broadcom with Buy Rating, Announces Price Target of $230

Management

The J.M. Smucker Co APPOINTS John Brase President And COO, Effective April 30, 2025

Arthur J. Gallagher & Co. Acquires First Capital Financial Services; Terms Not Disclosed

Hyster-Yale Announces Strategic Business Realignment Of Nuvera Fuel Cell Business

Raymond James analyst Srini Pajjuir maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and lowers the price target from $250 to $230.

AAPL

Raymond James Maintains Outperform on Apple, Lowers Price Target to $230

Ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AtriCure, revealing an average target of $52.5, a high estimate of $66.00, and a low estimate of $44.00. Marking an increase of 2.94%, the current average surpasses the previous average price target of $51.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746018071_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of AtriCure's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into AtriCure's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AtriCure analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into AtriCure's Background</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
<h3>AtriCure: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: AtriCure's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.64%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AtriCure's net margin is impressive, surpassing industry averages. With a net margin of -12.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AtriCure's ROE stands out, surpassing industry averages. With an impressive ROE of -3.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.54%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.17, AtriCure adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRC

14 Analysts Assess AtriCure: What You Need To Know

In the preceding three months, 32 analysts have released ratings for NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">17</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $171.41, a high estimate of $220.00, and a low estimate of $100.00. This current average represents a 4.53% decrease from the previous average price target of $179.55. 
<img src="https://www.benzinga.com/files/images/story/2025/1746018060_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive NVIDIA is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NVIDIA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of NVIDIA compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for NVIDIA's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into NVIDIA's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NVDA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NVIDIA analyst ratings.</a>
<h2>Get to Know NVIDIA Better</h2>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
<h3>NVIDIA's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: NVIDIA displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 77.94%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: NVIDIA's net margin excels beyond industry benchmarks, reaching 56.17%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): NVIDIA's ROE stands out, surpassing industry averages. With an impressive ROE of 30.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): NVIDIA's ROA stands out, surpassing industry averages. With an impressive ROA of 21.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: NVIDIA's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down NVIDIA: 32 Analysts Share Their Views

Comments

Fidelity MSCI COnsumer Staples Index ETF

ニュース

最新ニュース Fidelity MSCI COnsumer Staples Index ETF (ARCA:FSTA)

ニュース

パートナーシップ

ベンジンガ・グローバル